Lanean...
CRISPR/Cas Systems to Overcome Challenges in Developing the Next Generation of T Cells for Cancer Therapy
Genetically engineered immune cells with chimeric antigen receptors (CAR) or modified T cell receptors (TCR) have demonstrated their potential as a potent class of new cancer therapeutic strategy. Despite the clinical success of autologous CD19 CAR T cells in hematological malignancies, allogeneic T...
Gorde:
| Argitaratua izan da: | Adv Drug Deliv Rev |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7736063/ https://ncbi.nlm.nih.gov/pubmed/32707148 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.addr.2020.07.015 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|